

Research Article: New Research | Disorders of the Nervous System

The neuropsychiatric disease-associated gene *cacna1c* mediates survival of young hippocampal neurons

Role of *cacna1c* in young hippocampal neuron survival

Anni S. Lee^{1,2}, Héctor De Jesús-Cortés^{3,4}, Zeeba D. Kabir², Whitney Knobbe⁵, Madeline Orr⁵, Caitlin Burgdorf^{1,2}, Paula Huntington⁵, Latisha McDaniel⁴, Jeremiah K. Britt⁴, Franz Hoffmann^{6,7}, Daniel J. Brat⁸, Anjali M. Rajadhyaksha^{1,2,9} and Andrew A. Pieper^{4,10,11,12,13}

¹*Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, Cornell University, New York, NY*

²*Division of Pediatric Neurology, Department of Pediatrics, Weill Cornell Medicine, Cornell University, New York, NY*

³*Neuroscience Graduate Program, UT Southwestern Medical Center, Dallas, TX*

⁴*Department of Psychiatry, University of Iowa Carver College of Medicine, Iowa City, IA*

⁵*Department of Psychiatry, UT Southwestern Medical Center, Dallas, TX*

⁶*Institute of Pharmacology, Technical University Munich, Munich, Germany*

⁷*Research Group 923, Technical University Munich, Munich, Germany*

⁸*Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA*

⁹*Weill Cornell Autism Research Program, Weill Cornell Medical College, New York, NY*

¹⁰*Department of Neurology, University of Iowa Carver College of Medicine, Iowa City, IA*

¹¹*Department of Free Radical and Radiation Biology, University of Iowa Carver College of Medicine, Iowa City, IA*

¹²*Department of Veteran Affairs, University of Iowa Carver College of Medicine, Iowa City, IA*

¹³*Weill Cornell Autism Research Program, Weill Cornell Medicine, Cornell University, New York, NY*

DOI: 10.1523/ENEURO.0006-16.2016

Received: 4 January 2016

Revised: 12 February 2016

Accepted: 9 March 2016

Published: 24 March 2016

Author Contributions: A.S.L., H.D.J.-C., A.M.R., and A.A.P. designed research, performed research, analyzed data, wrote the paper; Z.D.K., W.K., M.O., C.B., P.H., L.M., and J.K.B. performed research, analyzed data; F.H. contributed reagents; D.J.B. performed research, analyzed data, wrote the paper.

Funding: University of Iowa Carver College of Medicine: Institutional Funds. The Hartwell Foundation: Collaborative Research Award. The Hartwell Foundation: Collaborative Research Award. National Science Foundation Fellowship; Weill Cornell Autism Research Funding; NIH: NRSA F31.

A.A.P. holds patents on the P7C3 family of neuroprotective compounds.

A.S.L. and H.D.J.-C. contributed equally to this work

Correspondence should be addressed to either Anjali Rajadhyaksha, PhD, Associate Professor of Neuroscience, Division of Pediatric Neurology, Department of Pediatrics, Weill Cornell Medicine, 1300 York Avenue, New York, NY 10065, USA, E-mail: amr2011@med.cornell.edu; or Andrew A. Pieper, MD, PhD, Professor of Psychiatry, Neurology and Free Radical & Radiation Biology, Department of Veterans Affairs, University of Iowa Carver College of Medicine, 415 Newton Road, Iowa City, IA 52242, USA, E-mail: Andrew-Pieper@uiowa.edu.

Cite as: eNeuro 2016; 10.1523/ENEURO.0006-16.2016

Alerts: Sign up at eneuro.org/alerts to receive customized email alerts when the fully formatted version of this article is published.

Accepted manuscripts are peer-reviewed but have not been through the copyediting, formatting, or proofreading process.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

eNeuro

<http://eneuro.msubmit.net>

eN-NWR-0006-16R1

The neuropsychiatric disease-associated gene *cacna1c* mediates survival of young hippocampal neurons.

TITLE PAGE

1. Manuscript Title

The neuropsychiatric disease-associated gene *cacna1c* mediates survival of young hippocampal neurons.

2. Abbreviated Title

Role of *cacna1c* in young hippocampal neuron survival

3. Authors

(1) and (2) are co-first authors
(12) and (13) are co-corresponding authors

1) Anni S. Lee

Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, Cornell University, New York, NY
Division of Pediatric Neurology, Department of Pediatrics, Weill Cornell Medicine, Cornell University, New York, NY

2) Héctor De Jesús-Cortés

Neuroscience Graduate Program, UT Southwestern Medical Center, Dallas, TX
Department of Psychiatry, University of Iowa Carver College of Medicine, Iowa City, IA

3) Zeeba D. Kabir

Division of Pediatric Neurology, Department of Pediatrics, Weill Cornell Medicine, Cornell University, New York, NY

4) Whitney Knobbe

Department of Psychiatry, UT Southwestern Medical Center, Dallas, TX

5) Madeline Orr

Department of Psychiatry, UT Southwestern Medical Center, Dallas, TX

6) Caitlin Burgdorf

Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, Cornell University, New York, NY
Division of Pediatric Neurology, Department of Pediatrics, Weill Cornell Medicine, Cornell University, New York, NY

7) Paula Huntington

Department of Psychiatry, UT Southwestern Medical Center, Dallas, TX

8) Latisha McDaniel

Department of Psychiatry, University of Iowa Carver College of Medicine, Iowa City, IA

9) Jeremiah K. Britt

Department of Psychiatry, University of Iowa Carver College of Medicine, Iowa City, IA

10) Franz Hoffmann

Institute of Pharmacology, Technical University Munich, Munich, Germany
Research Group 923, Technical University Munich, Munich, Germany

- 11) Daniel J. Brat
Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA
- 12) Anjali M. Rajadhyaksha
Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, Cornell
University, New York, NY
Division of Pediatric Neurology, Department of Pediatrics, Weill Cornell Medicine,
Cornell University, New York, NY
Weill Cornell Autism Research Program, Weill Cornell Medical College, New York, NY
- 13) Andrew A. Pieper
Department of Psychiatry, University of Iowa Carver College of Medicine, Iowa City, IA
Department of Neurology, University of Iowa Carver College of Medicine, Iowa City, IA
Department of Free Radical and Radiation Biology, University of Iowa Carver College of
Medicine, Iowa City, IA
Department of Veteran Affairs, University of Iowa Carver College of Medicine, Iowa City,
IA
Weill Cornell Autism Research Program, Weill Cornell Medicine, Cornell University, New
York, NY

4. Author Contributions

- 1) Anni S. Lee: Designed research, performed research, analyzed data, wrote the paper
- 2) Héctor De Jesús-Cortés: Designed research, performed research, analyzed data,
wrote the paper
- 3) Zeeba D. Kabir: performed research, analyzed data
- 4) Whitney Knobbe: performed research, analyzed data
- 5) Madeline Orr: performed research, analyzed data
- 6) Caitlin Burgdorf: performed research, analyzed data
- 7) Paula Huntington: performed research, analyzed data
- 8) Latisha McDaniel: performed research, analyzed data
- 9) Jeremiah K. Britt: performed research, analyzed data
- 9) Franz Hoffman: contributed reagents
- 10) Daniel J. Brat: performed research, analyzed data, wrote the paper
- 11) Anjali M. Rajadhyaksha: Designed research, performed research, analyzed data,
wrote the paper
- 12) Andrew A. Pieper: Designed research, performed research, analyzed data, wrote the
Paper

5. Correspondence

- 1) Anjali Rajadhyaksha, PhD
Associate Professor of Neuroscience
Division of Pediatric Neurology
Department of Pediatrics
Weill Cornell Medicine
1300 York Avenue
New York, NY USA 10065
(212-746-5999)
amr2011@med.cornell.edu

2) Andrew A. Pieper, MD, PhD
Professor of Psychiatry, Neurology and Free Radical & Radiation Biology
Department of Veterans Affairs
University of Iowa Carver College of Medicine
415 Newton Road
Iowa City, IA USA 52242
(319-353-5781)
Andrew-Pieper@uiowa.edu

6. Number of Figures: 4
7. Number of Tables: 0
8. Number of multimedia: 0
9. Number of words for Abstract: 194
10. Number of words for Significance Statement: 119
11. Number of words for Introduction: 627
12. Number of words for Discussion: 934
13. Acknowledgments: none other than funding listed below
14. Conflicts of Interest:
A.A.P. holds patents on the P7C3 family of neuroprotective compounds.
15. Funding Sources:
This work was supported by unrestricted funds from the University of Iowa Carver College of Medicine to A.A.P, a National Science Foundation fellowship to H.DJ-C, Funding from The Hartwell Foundation to A.M.R and A.A.P., Weill Cornell Autism Research Program funding to A. M. R, NIH Ruth L. Kirschstein NRSA F31 fellowship to A. S. L..

ABSTRACT

Genetic variations in *CACNA1C*, which encodes the Ca_v1.2 subunit of L-type calcium channels (LTCCs), are associated with multiple forms of neuropsychiatric disease that manifest high anxiety in patients. In parallel, mice harboring forebrain-specific conditional knockout of *cacna1c* (forebrain-Ca_v1.2 cKO) display unusually high anxiety-like behavior. LTCCs in general, including the Ca_v1.3 subunit, have been shown to mediate differentiation of neural precursor cells (NPCs). However, it has not previously been determined whether Ca_v1.2 affects postnatal hippocampal neurogenesis *in vivo*. Here, we show that forebrain-Ca_v1.2 cKO mice exhibit enhanced cell death of young hippocampal neurons, with no change in NPC proliferation, hippocampal size, dentate gyrus thickness, or corticosterone levels compared to wild type littermates. These mice also exhibit deficits in brain levels of brain-derived neurotrophic factor (BDNF), and Cre recombinase-mediated knockdown of adult hippocampal Ca_v1.2 recapitulates the deficit in young hippocampal neurons survival. Treatment of forebrain-Ca_v1.2 cKO mice with the neuroprotective agent P7C3-A20 restored the net magnitude of postnatal hippocampal neurogenesis to wild type levels without ameliorating their deficit in BDNF expression. The role of Ca_v1.2 in young hippocampal neurons survival may provide new approaches for understanding and treating neuropsychiatric disease associated with aberrations in *CACNA1C*.

SIGNIFICANCE STATEMENT

Aberrant postnatal hippocampal neurogenesis and *CACNA1C* mutations are associated with neuropsychiatric diseases manifesting high anxiety, and mice deficient in Cav1.2 neuronal expression display high anxiety-like behavior. Here, we report that these mice also display deficient postnatal hippocampal neurogenesis by virtue of elevated death of young hippocampal neurons, along with decreased expression of the endogenous pro-neurogenic agent brain-derived neurotrophic factor (BDNF). We further show that treatment of these mice with the neuroprotective agent P7C3-A20 circumvents the BDNF deficiency to safely and effectively normalize hippocampal neurogenesis without altering BDNF levels. Pharmacologic agents derived from the P7C3 family of neuroprotective compounds could thus provide a new therapeutic approach for treating patients suffering from neuropsychiatric disease associated with aberrations in *CACNA1C*.

INTRODUCTION

CACNA1C is one of the most widely reproduced risk genes for neuropsychiatric disorders (Heyes et al., 2015), including bipolar disorder (Psychiatric GWAS Consortium Bipolar Disorder Working Group, 2011; Ferreira et al., 2008; Sklar et al., 2008; Lee et al., 2011; Green et al., 2013; Nurnberger et al., 2014; Ament et al., 2015), schizophrenia (Nyegaard et al., 2010; Green et al., 2010; Ripke et al., 2013; Hamshere et al., 2013; Schizophrenia Working Group of the Psychiatric Genetics Consortium, 2014), and major depressive disorder (Green et al., 2010; Casamassima et al., 2010). *CACNA1C* was also recently identified in the largest human genome-wide association study to date as one of only two genes presenting a common risk factor across five major forms of neuropsychiatric illness: major depression, schizophrenia, bipolar disorder, autism and attention deficit hyperactivity disorder (ADHD) (Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013). It is not known, however, how *CACNA1C* exerts such pleiotropic effects on psychopathology.

CACNA1C encodes the voltage-gated L-type calcium channel (LTCC) $Ca_v1.2$, which allows cellular influx of calcium following transient changes in membrane potential. This ultimately activates downstream pathways of genetic transcription, such as for brain derived neurotrophic factor (BDNF) (Ghosh et al., 1994; Tao et al., 1998). $Ca_v1.2$ also plays an important role in synaptic plasticity related to neuropsychiatric illness and drug addiction (Giordano et al., 2010; Schierberl et al., 2012), reward-driven behavior (Wessa et al., 2010; Lancaster et al., 2014), fear conditioning (White et al., 2008; Langwieser et al., 2010), and cognition (Moosmang et al., 2005; White et al., 2008). Furthermore, $Ca_v1.2$, and not the other brain-specific LTCC subunit $Ca_v1.3$, mediates anxiety-like behavior in mice (Lee et al., 2012;

Dao et al., 2010). Specifically, mice harboring forebrain-specific conditional knockout of *cacna1c* (forebrain-Cav1.2 cKO) show elevated anxiety-like behavior in the light-dark conflict test, the open field test, and the elevated plus maze (Lee et al., 2010). Notably, anxiety is a prominent component of all forms of neuropsychiatric illness in which *CACNA1C* has been implicated.

Deisseroth et al. (2004) have previously shown a bi-directional regulatory role of LTCCs in adult-derived neural precursor cell proliferation *in vitro*, and Cav1.3 has recently been demonstrated to modulate both proliferation of postnatal neural precursor cells (NPCs) and survival of young hippocampal neurons in the hippocampus, such that elimination of Cav1.3 results in reduced size of the dentate gyrus (Marschallinger et al., 2015). This effect was related to expression of Cav1.3 in both immature NPCs (Nestin positive) and mature (NeuN positive) young hippocampal neurons, whereas Cav1.2 expression is restricted to only mature young hippocampal neurons (Marschallinger et al., 2015) in adult mice. However, it has not previously been determined whether Cav1.2 exerts a unique or complementary role in LTCC-mediated hippocampal neurogenesis, the net magnitude of which is a balance of proliferation of NPCs and survival of young hippocampal neurons into which NPCs differentiate. We sought to address this question because of the role of postnatal hippocampal neurogenesis in the broad spectrum of neuropsychiatric diseases in which aberrations in both *CACNA1C* (as described above) and postnatal hippocampal neurogenesis have been implicated, including major depression (Walker et al., 2014; Serafini et al., 2014), schizophrenia (Pieper et al., 2005; Pickard et al., 2006; Reif et al., 2007; Le Strat et al., 2009; Pickard 2011; Wu et al., 2013; Schreiber and Newman-Tancredi, 2014), bipolar disorder (Knight et al., 2011; Takamura et al., 2014; Nurnberger et al., 2014), autism (Amiri et al., 2012; Singh et al., 2013; Stanco et al., 2014), and ADHD (Dabe et al., 2013;

Ohira et al., 2013; Jolly et al., 2013; Kobayashi et al., 2014). Specifically, we applied forebrain-*Cav1.2* conditional deletion (cKO), as well as viral vector-mediated *cacna1c* gene elimination in adult mice, to quantify hippocampal neurogenesis and other neurophysiologic parameters following spatial and temporal manipulation of *Cav1.2* expression.

MATERIALS AND METHODS

Animals: All animal procedures were performed in accordance with the University of Iowa animal care committee's regulations. Animals were housed in temperature controlled conditions, provided food and water *ad libitum*, and maintained on a 12-hr light/dark cycle (7 A.M. to 7 P.M.). Male C57BL/6J mice were purchased from Jackson Laboratory. Forebrain- *Cav1.2* cKO mice were generated by crossing homozygous *cacna1c* (*Cav1.2*) floxed mice (*cacna1c^{fl/fl}*; Moosmang et al., 2010) with mice expressing Cre recombinase under the control of the alpha-CaMKII promoter (CaMKII-Cre). The CaMKII-Cre T29-1 line from Jackson Laboratories was used. In this line, Cre expression is activated at postnatal day 18, thereby circumventing early developmental compensatory adaptations. *HETs* and forebrain- *Cav1.2* cKO were indistinguishable from *WTs* in weight, development and general health.

BrdU Staining: After BrdU (Sigma-Aldrich) administration, mice were sacrificed at the described time-points by transcardial perfusion with 4% paraformaldehyde at pH 7.4 and brains were processed for immunohistochemical detection of incorporated BrdU in the hippocampus. Dissected brains were immersed in 4% paraformaldehyde overnight at 4 °C, then cryoprotected in sucrose before being sectioned into 40 µm thick free-floating sections. Unmasking of BrdU antigen was achieved through incubating tissue sections for two hours in 50% formamide / 2X saline-sodium citrate (SSC) at 65 °C, followed by a five minute wash in 2X SSC and subsequent

incubation for thirty minutes in 2M HCl at 37 °C. Sections were processed for immunohistochemical staining with mouse monoclonal anti-BrdU (1:100, Roche). The number of BrdU+ cells in the entire dentate gyrus SGZ was quantified by counting BrdU+ cells within the SGZ and dentate gyrus in every fifth section throughout the entire hippocampus, and then normalizing for dentate gyrus volume using Nikon Metamorph and NIH Image J software with appropriate conversion factors.

Surgery: Anesthesia was induced by intraperitoneal (i.p.) injection of ketamine (100 mg/kg)/xylazine cocktail (10 mg/kg). A midline incision was made, local anesthesia (Marcaine) applied, the head leveled and holes formed through the skull using a 25 gauge needle. Region-specific deletion of *cacna1c* was generated by manual bilateral infusion of AAV2/2-Cre-GFP (Vector BioLabs), (0.75 μ l/side) into the hippocampus of *cacna1c*^{flxed/flxed} mice through a 2.5 μ l Hamilton syringe at a rate of 0.1 μ l/minute. AAV2/2-GFP (Vector BioLabs) was used as a control. The coordinates for the hippocampus were anterior-posterior -2mm; medial-lateral \pm 1.6mm; dorsal-ventral -1.8mm, at a 10° angle. The needle was held in place for an additional 5 minutes after infusion in order to ensure complete delivery of virus. After a minimum of 3 weeks to allow for maximal Cre recombinase expression, mice were administered 50mg/kg BrdU for 5 days and transcardially perfused with 4% paraformaldehyde (PFA) 24hrs after the last injection of BrdU.

Fluorescent Immunohistochemistry: Cav1.2 fluorescent immunohistochemistry was performed to confirm elimination of Cav1.2. Fluorescent immunohistochemistry was also used to confirm injection placement. Mice were transcardially perfused with 4% PFA, and brains were dissected

and post-fixed overnight in 4% PFA followed by cryo- protection in 30% sucrose at 4°C for at least 72 hours. Forty μm -thick sections spanning the hippocampus were obtained using a sliding microtome and incubated in anti-chicken GFP (1:10,000, Aves Labs) and anti-rabbit glial fibrillary acidic protein (GFAP) (1:1000, Invitrogen) primary antibody over -night at 4°C. Sections were rinsed in 0.1M phosphate-buffer (PB) and incubated with donkey Alexa Fluor 488 (1:300) and Alexa Fluor 568 (1:300) antibody for 1 hour at room temperature. Doublecortin fluorescent immunohistochemistry was performed to analyze cells in the dentate gyrus that had recently committed to neuronal fate. Sections were incubated in anti-guinea pig Doublecortin (1:5,000, Millipore) primary antibody overnight at 4°C. Sections were rinsed in 0.1M phosphate-buffer (PB) and incubated with donkey Alexa Fluor 594 (1:400) antibody for 1 hour at room temperature. Sections were imaged using an epifluorescent microscope (Leica DM550B with Leica Application Suite Advanced Fluorescence 3.0.0 build 8134 software, Leica Microsystems Inc).

Q-PCR: To measure doublecortin (*DCX*) mRNA levels in forebrain Cav1.2 cKO mice and AAV2-2/2-Cre-GFP injected *cacna1c* floxed (*cacna1c^{fl/fl}*) mice, mice were euthanized by rapid decapitation and whole brains were rapidly dissected. Brain tissue was sectioned on a 1mm brain block. Dentate gyrus-containing tissue punches were obtained from forebrain Cav1.2 cKO and wild-type mice. For AAV2/2-Cre-GFP and AAV2/2-GFP injected mice, GFP goggles (BLS-Ltd.com) were used to visualize GFP signal in brain sections containing the dentate gyrus and to selectively dissect GFP positive tissue. Tissue punches were processed for total RNA isolation using the mirVana RNA isolation kit (Life Technologies, Grand Island, NY) and cDNA was synthesized from purified RNA using the High Capacity RNA-to-cDNA kit (Applied

Biosystems, Foster City, CA). Cav1.2 mRNA levels were measured using *cacna1c*-specific primers (Qiagen QuantiTect Primer assay QT00150752), and doublecortin (*DCX*) levels were measured using *DCX*-specific primers (Qiagen QuantiTect Primer assay QT02521155) on an ABI PRISM 7000 Sequence Detection System with SYBR Green PCR Master Mix (Applied Biosystems). Cycle threshold (Ct) values for target genes were normalized to the housekeeping gene *gapdh* (QuantiTect Primer assay QT01658692, Qiagen). Each experiment was performed in triplicate and values were averaged.

BDNF ELISA: Mature BDNF protein level was measured using the BDNF Emax ImmunoAssay (ELISA) system (Promega), with recombinant mature BDNF as a standard. Standard and samples were performed in duplicate, with each group containing 10 to 14 samples. Protein was extracted and quantified following the manufacturer protocol. Tissue samples were homogenized in lysis buffer (150mM NaCl, 1% Triton X-100, 25mM HEPES, 2mM NaF) containing phosphatase and protease inhibitors, and then incubated by rotation at 4°C for 1 hour. Homogenized tissue was centrifuged at maximum speed and the supernatant containing total protein was collected and quantified using the BCA protein assay kit (Thermo Fisher Scientific). Each sample was diluted 1:1 with block and sample buffer (BSB), and placed in designated wells of a 96-well plate previously coated with BDNF antibody in carbonate buffer (25mM Na₂CO₃ and 25mM Na₂HCO₃, pH 9.7, incubated at 4°C), followed by blocking with BSB. A second coating of primary anti-human BDNF antibody was added, followed by horseradish peroxidase-conjugated secondary antibody. The colorimetric reaction was initiated by tetramethylbenzidine. After 10 minutes, the reaction was stopped by addition of 1N HCl, and absorbance was read at 450 nm on a plate reader (iMark Absorbance Microplate Reader, Bio-Rad Laboratories).

Corticosterone levels: To measure baseline and stress-induced corticosterone levels, plasma samples were isolated from 7-15 week old forebrain-Cav1.2 cKO and wild type mice at 1:00-2:00pm. Plasma was isolated from trunk blood. Blood was allowed to sit at room temperature for 60 minutes and spun at 1200x g for 15mins. Supernatant was isolated and stored at -20°C. For all restraint stress experiments, mice were restrained for 30min in decapicones. Plasma corticosterone levels were measured using the high sensitivity corticosterone enzyme immunoassay (EIA) kit (AC-15F1, Immunodiagnostic Systems). Samples were analyzed in duplicate. Concentrations were determined as per manufacturer's instructions.

Morphometric Analysis of Hippocampal Size: 4% paraformaldehyde-fixed mouse brains were sectioned in the coronal plane, paraffin-embedded, sectioned at 8 μ M thickness, and stained with hematoxylin & eosin. Histological sections were obtained at 50- μ m intervals. Measurements of the hippocampus, dentate granular cell layer, and forebrain were taken at the coronal level in which CA1 approaches the midline and the upper blade of the dentate gyrus runs parallel to the surface of the brain. An ocular lens fitted with an etched grid was used to measure the dentate, CA1 and CA3 height and neuronal size (60X), as well as hippocampal dimensions (2X).

P7C3-A20 treatments: All mice were single housed for the duration of treatment. Forebrain-Cav1.2 cKO and wild type littermate mice received 10mg/kg P7C3-A20 or vehicle (5% DMSO, 20% cremaphor in 5% dextrose), intraperitoneally, (i.p), twice a day for 30 days, starting at P21. This dose of P7C3-A20 was chosen based on efficacy in multiple animal models of neuroprotection (Yin et al., 2014; Tesla et al., 2012; De Jesus-Cortes et al., 2012). Mice were

transcardially perfused with 4% PFA 24hrs after the last BrdU injection. In separate experiments, brains were flash frozen and processed for BDNF ELISA.

Statistics: For all experiments, data was first analyzed for normality using a Shapiro-Wilk test. If the data was normally distributed, a parametric independent-samples t test or two-way ANOVA test was then applied. For data that was not normally distributed, a non-parametric independent-samples Mann-Whitney U test (as specified in figure legends), was applied. A value of $p \leq 0.05$ was considered to be statistically significant and all analyses were performed using SPSS version 19 (SPSS Inc, Chicago, Illinois). Graphs were constructed in GraphPad Prism version 6.0 for Mac, San Diego California USA.

Results

Ca_v1.2 channels support postnatal hippocampal neurogenesis.

To examine the net magnitude of adult hippocampal neurogenesis, which results from the balance of proliferation of NPCs and survival of young adult hippocampal neurons into which NPCs differentiate, in forebrain-Ca_v1.2 cKO mice, all mice received intraperitoneal (i.p.) injections of the thymidine analog bromodeoxyuridine (BrdU, 50 mg/kg/d) once daily for 5 days. Mice were then sacrificed for immunohistochemical analysis of the brain 24 hours after the final BrdU injection. Compared to wild type littermates, forebrain-Ca_v1.2 cKO mice showed approximately 50% fewer BrdU⁺ cells throughout the hippocampus (Fig. 1A, 1B; $F_{1,7} = 57.714$; $p = .004$). These mutant mice also exhibited significantly lower expression of doublecortin (Fig 1C, 1D, $F_{1,11} = 24.928$; $p < .001$), a microtubule-associated protein that serves as a marker of

neurogenesis by virtue of transient expression in newly formed neurons between their birth and final maturation (Brown et al., 2003).

In order to directly evaluate the effect of spatially- and temporally-specific elimination of $Ca_v1.2$ in the adult hippocampus, and thus differentiate between an adult versus developmental effect of $Ca_v1.2$ on postnatal hippocampal neurogenesis, we next stereotactically delivered AAV2/2-Cre-GFP into the dentate gyrus of adult *cacna1c^{fl/fl}* mice. This resulted in significantly lower levels of $Ca_v1.2$ mRNA compared to control AAV2/2-GFP injected mice (Fig. 2A, $F_{1,9} = 31.536$; $p < .001$). As with forebrain- $Ca_v1.2$ cKO mice, focal knockout of $Ca_v1.2$ in the adult dentate gyrus resulted in about a 50% reduction in BrdU+ cells, compared to control mice injected with AAV2/2-GFP (Fig. 2B, $F_{1,14} = 165.989$; $p < 0.001$).

$Ca_v1.2$ channels are necessary for survival of young hippocampal neurons, and not for proliferation of neural precursor cells.

The net magnitude of postnatal hippocampal neurogenesis is a balance of proliferation of NPCs and survival of the young hippocampal neurons into which NPCs differentiate, and indeed about 40% of young hippocampal neurons normally die within the first week of their birth (Pieper et al., 2010). Recently, $Ca_v1.3$ has been shown to be essential for both of these processes (Marschallinger et al., 2015). Therefore, we investigated whether $Ca_v1.2$ was necessary for proliferation of NPCs, survival of young hippocampal neurons, or both. To address this question, adult forebrain- $Ca_v1.2$ cKO mice were injected with a single bolus of BrdU (150mg/kg, i.p.), followed by transcardial perfusion either 1 hour later (to measure proliferation of NPCs; Fig 3A) or 30 days later (to measure survival of young hippocampal neurons; Fig 3C), per established methods (Pieper et al., 2010). We observed no difference in the number of BrdU+ cells at the one

hour time point between forebrain-Ca_v1.2 cKO mice and wild type littermates (Fig 3B, $F_{1,6} = .039$; $p = .935$), indicating that in contrast to Ca_v1.3, Ca_v1.2 does not affect NPC proliferation. However, forebrain-Ca_v1.2 cKO mice exhibited an approximately 50% lower number of BrdU+ cells relative to wild type littermates 30 days after BrdU injection (Fig 3D, $F_{1,11} = 18.082$; $p = .002$), demonstrating that Ca_v1.2 is necessary for survival of young hippocampal neurons.

Forebrain-Ca_v1.2 cKO mice display deficient levels of hippocampal BDNF, with normal glucocorticoid levels and hippocampal size.

Since brain derived neurotrophic factor (BDNF) has been shown to support postnatal hippocampal neurogenesis (Duman and Monteggia, 2006; Chen et al., 2015), and brain levels of BDNF are regulated by L-type calcium channels (Ghosh et al., 1994; Tao et al., 1998), we wondered whether hippocampal levels of BDNF might be altered in forebrain-Ca_v1.2 cKO mice. Via ELISA, we found that forebrain-Ca_v1.2 cKO mice have significantly lower hippocampal BDNF protein levels compared to WT littermates (Fig 3E, $F_{1,15} = 11.105$; $p = .005$).

Next, since glucocorticoid receptors have been shown to modulate connectivity and integration of young hippocampal neurons (Fitzsimons et al., 2013), and forebrain-Ca_v1.2 cKO mice display markedly high levels of anxiety-like behavior that is often associated with elevated levels of stress hormones in animal models, we wondered whether corticosterone levels might also be altered in forebrain-Ca_v1.2 cKO mice. Enzyme immunoassay revealed differences in corticosterone levels between basal and stressed groups of each genotype (Fig 3F, $F_{1,47} = 104.1$; $p < .001$). However, there were no genotype-specific differences in either basal- or stressed-condition corticosterone levels between forebrain-Ca_v1.2 cKO and wild type littermate mice (Fig

3F, $F_{1,47} = .6526$; $p = .423$), demonstrating that lower adult neurogenesis in forebrain $Ca_v1.2$ cKO mice is not due to altered corticosterone levels.

Finally, because other mouse models with severe deficits in postnatal hippocampal neurogenesis have been shown to harbor abnormal hippocampal morphology (Pieper et al., 2005), we compared hippocampal morphology in forebrain- $Ca_v1.2$ cKO mice with wild type littermates. Notably, forebrain- $Ca_v1.2$ cKO mice displayed normal overall hippocampal size, as well as normal thickness of the dentate gyrus ($F_{1,13} = .022$; $p = .986$), CA1 ($F_{1,13} = .443$; $p = .518$) and CA3 ($F_{1,13} = .056$; $p = .898$) subregions (Fig 3G).

P7C3-A20 rescues survival of young hippocampal neurons in forebrain- $Ca_v1.2$ cKO mice without affecting BDNF levels.

Recently, the novel aminopropyl carbazole P7C3-class of compounds has been discovered and characterized in *in vivo* models of neuron cell death, including protection of young hippocampal neurons that thereby increases the net magnitude of postnatal hippocampal neurogenesis (Pieper et al., 2010, Macmillan et al., 2011; Pieper et al., 2014). Active members of this chemical series have been shown to enhance flux of the nicotinamide adenine dinucleotide (NAD) salvage pathway in normal mammalian cells, and facilitate NAD rebound following doxorubicin exposure (Wang et al., 2014). To date, these compounds have shown neuronal protective efficacy in multiple preclinical models of neuropsychiatric disorders, such as Parkinson's disease (De Jesus-Cortes et al., 2012, 2015; Naidoo et al., 2014), amyotrophic lateral sclerosis (Tesla et al., 2012), stress-associated depressive-like behavior (Walker et al., 2015), aging-associated cognitive decline (Pieper et al., 2010), peripheral nerve crush injury (Kemp et al., 2015), and traumatic brain injury (Blaya et al., 2014; Yin et al., 2014, Dutca et al., 2014). We therefore

wondered whether treatment of forebrain-Ca_v1.2 cKO mice with P7C3-A20, one of the most highly active agents in the P7C3 series, might restore to normal the net magnitude of hippocampal neurogenesis. Indeed, one-month treatment with P7C3-A20 starting at weaning age fully restored neurogenesis in forebrain-Ca_v1.2 cKO mice to wild-type levels, as determined by BrdU-labeling (Fig 4A,B; two-way ANOVA, treatment, $F_{1,8} = 18.99$, $p < .001$; genotype, $F_{1,8} = 50.97$, $p = .002$) and levels of doublecortin (Fig 4C,D; two-way ANOVA, treatment, $F_{1,28} = 41.84$, $p < .001$; genotype, $F_{1,28} = 8.568$; $p = .007$). Notably, treatment with P7C3-A20 had no effect on hippocampal BDNF levels (Fig 4E; two-way ANOVA, treatment, $F_{1,23} = .1567$, $p = .696$, genotype $F_{1,23} = 18.45$, $p < .001$). Thus, despite the profound deficit in hippocampal BDNF levels in forebrain-Ca_v1.2 cKO mice, deficient neurogenesis in this model can still be corrected by BDNF-independent mechanisms.

DISCUSSION

Here, we demonstrate a previously unidentified role of Ca_v1.2 in regulating survival of young hippocampal neurons in living mice by studying both forebrain-Ca_v1.2 cKO mice and viral vector-mediated specific hippocampal elimination of Ca_v1.2 within young hippocampal neurons in adult wild type mice. Our *in vivo* data is consistent with a previous *in vitro* study identifying a role of LTCCs in activity-dependent regulation of adult-derived NPCs *in vitro* (Deisseroth et al., 2004), as well as another recent *in vitro* study demonstrating involvement of LTCCs in survival and maturation of newly generated neurons using a clonal line of NPCs established from adult rat hippocampus (Teh et al., 2014). Given the role of hippocampal neurogenesis in multiple forms of neuropsychiatric disease, our findings provide new insight into the potential role of Ca_v1.2 in the multiple forms of mental illness in which it has been implicated.

We have observed that in the absence of $Ca_v1.2$, young hippocampal neurons die at an accelerated rate of approximately 50%. Moreover, even though forebrain- $Ca_v1.2$ cKO mice display abnormally high anxiety-like behavior (Lee et al., 2012a), and high corticosterone levels associated with stress are known to reduce hippocampal neurogenesis (Cameron et al., 1994; Yu et al., 2010), these mice show normal levels of baseline and stressed brain corticosterone, indicating that their deficit in neurogenesis is not due to secondary effects of abnormally high anxiety.

The observed effect of elimination of $Ca_v1.2$ on survival of young hippocampal neurons is in contrast to what was recently described for genetic elimination of $Ca_v1.3$, which exerts a more profound effect on hippocampal neurogenesis by regulating both proliferation of NPCs and survival of young hippocampal neurons, resulting in reduced hippocampal size (Marschallinger et al., 2015). Presumably, the differential roles of these two major forms of LTCCs in the brain are related to the fact that within the hippocampal neurogenic niche $Ca_v1.2$ is expressed exclusively in mature (NeuN-positive cells) young hippocampal neurons, whereas $Ca_v1.3$ is expressed in both newly formed immature NPCs (nestin-positive cells) and mature young hippocampal neurons (Marschallinger et al., 2015). An interesting question that will be addressed in future studies is whether this is a cell autonomous or non-autonomous effect. The latter is certainly likely, given that $Ca_v1.2$ mediates BDNF production, which can be released from cells to act on both secreting and neighboring neurons. The fact that genetic deletion of $Ca_v1.3$ also results in diminished hippocampal size (Marschallinger et al., 2015) suggests that $Ca_v1.3$ could play a role in both developmental and postnatal neurogenesis. Here, we show that genetic deletion of $Ca_v1.2$, by contrast, has no effect on hippocampal size, suggesting that $Ca_v1.2$ plays a specific role in regulating survival of young hippocampal neurons in the mature brain

rather than during development. Indeed, we have demonstrated an essential role of Cav1.2 in postnatal hippocampal neurogenesis by viral vector-mediated elimination in adult mice.

Apparently, under non-pathologic conditions in the adult animals tested, this decreased survival of young hippocampal neurons is not sufficient to reduce hippocampal size. Future experiments in animals under circumstances of increased cellular stress, such as occurs with injury or ageing, will help determine whether decreased survival of young hippocampal neurons in this model compromises overall morphology of the dentate gyrus under stressed conditions. Taken together, these results suggest that dynamic modulation of Cav1.2-mediated signaling in the adult brain might help ameliorate related disease symptoms.

LTCC signaling has been linked to BDNF production in hippocampal neurons (Ghosh et al., 1994), and we report here for the first time that the brains of forebrain-Cav1.2 cKO mice are deficient in hippocampal levels of BDNF. LTCCs serves as a primary Ca²⁺ source of BDNF synthesis via transcriptional regulation of the promoter for *Bdnf* exon IV, which represents the most highly-expressed *bdnf* splice variant (West et al., 2014). Multiple LTCC-activated transcriptional regulators, including CREB, Ca²⁺ response factor (CaRF) and MeCP2, control *bdnf* expression by binding to the promoter of *bdnf* exon IV (Tao et al 1998; Tao et al., 2002; Tao et al 2009; Chao, Zoghbi 2009; Chen 2003), and we propose that the lack of activation of these factors in the hippocampus results in lower BDNF in the forebrain of Cav1.2 KO mice. BDNF is known to support neurogenesis, but has not proven to be an effective therapeutic agent to date. We show here that extended treatment of forebrain-Cav1.2 cKO mice with the neuroprotective aminopropyl carbazole P7C3-A20 restored hippocampal neurogenesis to normal levels by ameliorating the aberrantly high rate of death of young hippocampal neurons in these mice. This therapeutic effect was achieved without affecting hippocampal BDNF levels,

suggesting that P7C3 compounds offer an alternative therapeutic route to restore neurogenesis in a manner that circumvents deficient BDNF signaling through an independent mechanism.

The net magnitude of postnatal hippocampal neurogenesis is a balance of proliferation of NPCs and survival of the ensuing young hippocampal neurons. Future experiments will address the impact of restoring the net magnitude of hippocampal neurogenesis to normal levels in forebrain-Cav1.2 cKO mice, as hippocampal neurogenesis has been linked to anxiety and depression-like behavior, as well as learning and memory. Such behavioral studies will provide important clarification of the relationship between the observed neural changes and risk for pathology-associated behaviors in this model. Finally, our identification of a new role for Cav1.2 in neuronal cell survival may provide new insight and approaches to treating neuropsychiatric disease. Future experiments will examine whether Cav1.2 also serves a selective role in mediating mature neuronal cell death as well. In conclusion, the results of our work may provide new treatment opportunities for patients suffering from neurodegenerative disease, including forms of mental illness associated with neuronal cell death.

REFERENCES

- Ament SA et al. (2015) Rare variants in neuronal excitability genes influence risk for bipolar disorder. *Proc Natl Acad Sci USA* 112: 3576-81.
- Amiri A, Cho W, Zhou J, Birnbaum SG, Sinton CM, McKay RM, Parada LF (2012) Pten deletion in adult hippocampal neural stem/progenitor cells causes cellular abnormalities and alters neurogenesis. *J Neurosci* 32:5880-90.
- Blaya MO, Bramlett HM, Naidoo J, Pieper AA, Dietrich WD (2014) Neuroprotective efficacy of a proneurogenic compound after traumatic brain injury. *J Neurotrauma* 31:476-86.
- Brown JP, Couillard-Despres S, Cooper-Kuhn CM, Winkler J, Aigner L, Kuhn HG (2003) Transient expression of doublecortin during adult neurogenesis. *J Comp Neurol* 467:1-10.
- Busquet P, Nguyen NK, Schmid E, Tanimoto N, Seeliger MW, Ben-Yosef T, Mizuno F, Akopian A, Striessnig J, Singewald N (2010) Cav1.3 L-type Ca²⁺ channels modulate depression-like behavior in mice independent of deaf phenotype. *Int J Neuropsychopharmacol* 13:499-513.
- Cameron HA and Gould E. (1994) Adult neurogenesis is regulated by adrenal steroids in the dentate gyrus. *Neuroscience* 61: 203–209.

Casamassima, F., et al. (2010) Phenotypic effects of a bipolar liability gene among individuals with major depressive disorder. *Am J Med Genet B Neuropsychiatr Genet* 153B: 303-309.

Chao HT, Zoghbi HY (2009) The yin and yang of MeCP2 phosphorylation. *Proc Natl Acad Sci USA* 106: 4577-8.

Chen WG, Chang Q, Lin Y, Meissner A, West AE, Griffith EC, Jaenisch R, Greenberg ME (2003) *Science* 302:885-9.

Cross-Disorder Group of the Psychiatric Genomics Consortium (2013) Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. *Lancet* 381: 1371-9.

Cuccurazzu B, Leone L, Podda MV, Piacentini R, Riccardi E, Ripoli C, Azzena GB, Grassi C (2010) Exposure to extremely low-frequency (50 Hz) electromagnetic fields enhances adult hippocampal neurogenesis in C57BL/6 mice. *Exp Neurol* 226:173-82.

Dabe EC, Majdak P, Bhattacharya TK, Miller DS, Rhodes JS (2013) Chronic D-amphetamine administered from childhood to adulthood dose-dependently increases the survival of new neurons in the hippocampus of male C57BL/6J mice. *Neuroscience* 231:125-35.

Dao DT, Mahon PB, Cai X, Kovacsics CE, Blackwell RA, Arad M, Shi J, Zandi PP, O'Donnell P; Bipolar Genome Study (BiGS) Consortium, Knowles JA, Weissman MM, Coryell W, Scheftner

WA, Lawson WB, Levinson DF, Thompson SM, Potash JB, Gould TD (2010) Mood disorder susceptibility gene CACNA1C modifies mood-related behaviors in mice and interacts with sex to influence behavior in mice and diagnosis in humans. *Biol Psych* 68:801–10.

De Jesus-Cortes H, Xu P, Drawbridge J, Estill SJ, Huntington P, Tran S, Britt J, Tesla R, Morlock L, Naidoo J, Melito LM, Wang G, Williams NS, Ready JM, McKnight SL, Pieper AA (2012) *Proc Natl Acad Sci USA* 109:17010-5.

De Jesus Cortes H, Miller AD, Britt JK, DeMarco AJ, De Jesus-Cortes M, Steubing E, Naidoo J, Wasquez-Rosa W, Morlock L, Williams NS, Ready JM, Narayanan NS, Pieper AA (2015) P7C3-S243 protects rats in the 6-hydroxydopamine model of Parkinson's disease. *npj Parkinson's Disease*: 15010

Deisseroth K, Singla S, Toda H, Monje M, Palmer TD, Malenka RC (2004) Excitation-neurogenesis coupling in adult neural stem/progenitor cells. *Neuron* 42:535-52.

Duman and Monteggia (2006) A neurotrophic model for stress-related mood disorders. *Biol Psychiatry* 59(12):1116-27.

Dutca LM, Stasheff SF, Hedberg-Buenz A, Rudd DS, Batra N, Blodi FR, Yorek MS, Yin T, Shankar M, Herlein JA, Naidoo J, Morlock L, Williams N, Kardon RH, Anderson MG, Pieper AA, Harper MM (2014) Early detection of subclinical visual damage after blast-mediated TBI

enables prevention of chronic visual deficit by treatment with P7C3-S243. *Invest Ophthalmol Vis Sci* 55:8330-41.

Ferreira MA, et al. (2008) Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. *Nat Genet* 40: 1056-1058.

Fitzsimons CP, van Hooijdonk LW, Schouten M, Zalachoras I, Brinks V, Zheng T, Schouten TG, Saaltink DJ, Dijkmans T, Steindler DA, Verhaagen J, Verbeek FJ, Lucassen PJ, de Kloet ER, Meijer OC, Karst H, Joels M, Oitzl MS, Vreugdenhil E (2013) Knockdown of the glucocorticoid receptor alters functional integration of newborn neurons in the adult hippocampus and impairs fear-motivated behaviors. *Mol Psychiatry* 18:993-1005.

Ghosh A, Carnahan J, Greenberg ME (1994) Requirement for BDNF in activity-dependent survival of cortical neurons. *Science* 263:1618-23.

Girodano TP, Tropea TF, Satpute SS, Sinnegger-Brauns MJ, Striessnig J, Kosofsky BE, Rajadhyaksha AM (2010) Molecular switch from L-type Cav1.3 to Cav1.2 C12+ channel signaling underlies long-term psychostimulant-induced behavioral and molecular plasticity. *J Neuroscience* 30: 17051-62.

Green EK, et al (2010) The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia. *Mol Psychiatry* 15: 1016-1022.

Green EK, Hamshere M, Forty L, Gordon-Smith K, Fraser C, Russell E, Grozeva D, Kirov G, Holmans P, Moran JL, Purcell S, Sklar P, Owen MJ, O'Donovan MC, Jones L, Jones IR, Craddock N (2013) Replication of bipolar disorder susceptibility alleles and identification of two novel genome-wide significant associations in a new bipolar disorder case-control sample. *Mol Psychiatry* 18: 1302-1307.

Hamshere ML, Walters JT, Smith R, Richards AL, Green E, Grozeva D, Jones I, Forty L, Jones L, Gordon-Smith K, Riley B, O'Neill FA, Kendler KS, Sklar P, Purcell S, Kranz J; Schizophrenia Psychiatric Genome-wide Association Study Consortium; Wellcome Trust Case Control Consortium+; Wellcome Trust Case Control Consortium 2. Morris D, Gill M, Holmans P, Craddock N, Corvin A, Owen MJ, O'Donovan MC (2013) Genome-wide significant associations in schizophrenia to ITIH3/4, CACNA1C and SDCCAG8, and extensive replication of associations reported by the Schizophrenia PGC. *Mol Psychiatry* 18:708-12/

Heyes S, Pratt WS, Rees E, Dahimene S, Ferron L, Owen MJ, Dolphin AC (2015) Genetic disruption of voltage-gated calcium channels in psychiatric and neurological disorders. *Prog Neurobiol*: <http://dx.doi.org/10.1016/j.pneurobio.2015.09.002>

Jolly LA, Homan CC, Jacob R, Barry S, Gez J (2013) The UPF3B gene, implicated in intellectual disability, autism and ADHD and childhood onset schizophrenia regulates neural progenitor cell behavior and neuronal outgrowth. *Hum Mol Genet* 22: 4673-87.

Kemp SW, Szykaruk M, Stanoulis KN, Wood MD, Liu EH, Willand MP, Morlock L, Naidoo J, Williams NS, Ready JM, Mangano TJ, Beggs S, Salter MW, Gordon T, Pieper AA, Borschel GH (2015) Pharmacologic rescue of motor and sensory function by the neuroprotective compound P7C3 following neonatal nerve injury. *Neuroscience* 284:202-16.

Knight HM, Walker R, James R, Porteous DJ, Muir WJ, Blackwood DH, Pickard BS (2012) GRIK4/KA1 protein expression in human brain and correlation with bipolar disorder risk variant status. *Am J Med Genet B Neuropsychiatr Genet* 159B:21-9.

Kobayashi M, Makatani T, Koda T, Matsumoto K, Ozaki R, Mochida N, Takao K, Miyakawa T, Matsuoka I (2014) Absence of BRINP1 in mice causes increase of hippocampal neurogenesis and behavioral alterations relevant to human psychiatric disorders. *Mol Brain* 7:12.

Lancaster TM, Heerey EA, Mantripragada K, Linden DE (2014) CACNA1C risk variant affects reward responsiveness in healthy individuals. *Transl Psychiatry* 4:e461.

Langwieser N, Christel CH, Kleppisch T, Hofmann F, Wotjak CT, Moosmang S (2010) Homeostatic switch in hebbian plasticity and fear learning after sustained loss of Cav1.2 calcium channels. *J Neurosci* 30:8367-75.

Lee et al. (2011) Genome-wide association study of bipolar 1 disorder in the Han Chinese population. *Mol Psychiatry* 16: 548-56.

Lee AS, Ra S, Rajadhyaksha AM, Britt JK, De Jesus-Cortes H, Gonzales KL, Lee A, Moosmang S, Hofman F, Pieper AA, Rajadhyaksha AM (2012a) Forebrain elimination of cacna1c mediates anxiety-like behavior in mice. *Mol Psych* 17:1054-5.

Lee AS, Gonzales KL, Lee A, Moosmang S, Hofmann F, Pieper AA, Rajadhyaksha AM (2012b) Selective genetic deletion of cacna1c in the mouse prefrontal cortex. *Mol Psych* 17:1051.

Le Strat Y, Ramoz N, Gorwood P (2009) The role of genes involved in neuroplasticity and neurogenesis in the observation of a gene-environment interaction (GxE) in schizophrenia. *Curr Mol Med* 9:506-18.

MacMillan KS, Naidoo J, Liang J, Melito L, Williams NS, Morlock L, Huntington PJ, Estill SJ, Longgood J, Becker GL, McKnight SL, Pieper AA, De Brabander JK, Ready JM (2011) Development of proneurogenic, neuroprotective small molecules. *J Am Chem Soc* 133:1428-37.

Marschallinger J, Sah A, Schmuckermair C, Unger M, Rotheneichner P, Kharitonova M, Waclawiczek A, Gerner P, Jaksch-Bogensperger H, Berger S, Striessnig J, Singewald N, Couillard-Despres S, Aigner L (2015) The L-type calcium channel Cav1.3 is required for proper hippocampal neurogenesis and cognitive functions. *Cell Calcium* 58: 606-16.

McKinney BC, Murphy GG (2006) The L-Type voltage-gated calcium channel Cav1.3 mediates consolidation, but not extinction, of contextually conditioned fear in mice. *Learn Mem* 13:584-9.

Miller BR, Hen R (2015) The current state of the neurogenic theory of depression and anxiety.

Curr Opin Neurobiol 30:51-8.

Moosmang S, Haider N, Klugbauer N, Adelsberger H, Langwieser N, Muller J, Stiess M, Marais

E, Schulla V, Lacinova L, Goebbels S, Nave KA, Storm DR, Hofmann F, Kleppisch T (2005)

Role of hippocampal Cav1.2 Ca²⁺ channels in NMDA receptor-independent synaptic plasticity and spatial memory. J Neuroscience 25:9883-92.

Naidoo J, De Jesus-Cortes H, Huntington P, Estill S, Morlock LK, Starwalt R, Mangano TJ,

Williams NS, Pieper AA, Ready JM (2014) Discovery of a neuroprotective chemical, (S)-N-(3-

(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-6-methoxy-pyridin-2-amine[(-)-P7C3-S243],

with improved druglike properties. J Med Chem 57:3746-54.

Nurnberger Jr. JI, Koller DL, Jung J, Eenberg HJ, Foroud T, Guella I, Vawter MP, Kelsoe JR

(2014) Identification of pathways for bipolar disorder: a meta-analysis. JAMA Psychiatry 71:

657-64.

Nyegaard, M., et al. (2010) CACNA1C (rs1006737) is associated with schizophrenia. Mol

Psychiatry 15: 119-121.

Ohira K, Kobayashi K, Toyama K, Nakamura HK, Shoji H, Takao K, Takeuchi R, Yamaguchi S,

Kataoka M, Otsuka S, Takahashi M, Miyakawa T (2013) Synaptosomal-associated protein 25

mutations induces immaturity of the dentate granule cells of adult mice. Mol Brain 6:12.

Pickard BS, Pieper AA, Porteous DJ, Blackwood DH, Muir WJ (2006) The NPAS3 gene – emerging evidence for a role in psychiatric illness. *Ann Med* 38:439-48.

Pickard B (2011) Progress in defining the biological causes of schizophrenia. *Expert Rev Mol Med* 13:e25.

Pieper AA, Wu X, Han TW, Estill SJ, Dang Q, Wu LC, Reece-Fincannon S, Dudley CA, Richardson JA, Brat DJ, McKnight SL (2005) The neuronal PAS domain protein 3 transcription factor controls FGF-mediated adult hippocampal neurogenesis in mice. *Proc Natl Acad Sci USA* 102:14052-7.

Pieper AA et al. (2010) Discovery of a proneurogenic, neuroprotective chemical. *Cell* 142:39-51.

Pieper AA, McKnight SL, Ready JM (2014) P7C3 and an unbiased approach to drug discovery for neurodegenerative diseases. *Chem Soc Rev* 43:6716-26.

Psychiatric GWAS Consortium Bipolar Disorder Working Group (2011). Large scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. *Nat. Genet.* 43, 977–983.

Reif A, Schmitt A, Fritzen S, Lesch KP (2007) Neurogenesis and schizophrenia: dividing neurons in a divided mind? *Eur Arch Psychiatry Clin Neurosci* 257:290-9.

Ripke, S., O'Dushlaine, C., Chambert, K., Moran, J.L., Kahler, A.K., Akterin, S., Bergen, S.E., Collins, A.L., Crowley, J.J., Fromer, M., et al. (2013) Multicenter Genetic Studies of Schizophrenia Consortium; Psychosis Endophenotypes International Consortium; Wellcome Trust Case Control Consortium 2 (2013). Genome-wide association analysis identifies 13 new risk loci for schizophrenia. *Nat. Genet.* 45, 1150–1159.

Schierberl K, Hao J, Tropea TF, Ra S, Giordano TP, Xu Q, Garraway SM, Hofmann F, Moosmang S, Striessnig J, Inturrisi CE, Rajadhyaksha AM (2011) Cav1.2 L-type Ca²⁺ channels mediate cocaine-induced GluA1 trafficking in the nucleus accumbens, a long-term adaptation dependent on ventral tegmental area Ca(v)1.3 channels. *J Neurosci* 31:13562-75.

Schierberl K, Giordano T, Satpute S, Hao J, Kaur G, Hofmann F, Moosmang S, Striessnig J, Rajadhyaksha A (2012) Cav1.3 L-type Ca²⁺ channels mediate long-term adaptation in dopamine D2L-mediated GluA1 trafficking in the dorsal striatum following cocaine exposure. *Channels* 6:11-7.

Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) Biological insights from the 108 schizophrenia-associated genetic loci. *Nature* 511:421-7.

Schreiber R, Newman-Tancredi A (2014) Improving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT(1A) receptor activation. *Neurobiol Learn Mem* 110:72-80.

- Serafini G, Hayley S, Pompili M, Dwivedi Y, Brahmachari G, Girardi P, Amore M (2014) Hippocampal neurogenesis, neurotrophic factors and depression: possible thereapeutic targets? *CNS Neurol Disord Drug Targets* 13:1708-21.
- Singh C, Bortolato M, Bali N, Godar SC, Scott AL, Chen K, Thompson RF, Shih JC (2013) Cognitive abnormalities and hippocampal alterations in monoamine oxidase A and B knockout mice. *Proc Natl Acad Sci USA* 110:12816-21.
- Sklar, P., Smoller, J.W., Fan, J., Ferreira, M.A., Perlis, R.H., Chambert, K., Nimgaonkar, V.L., McQueen, M.B., Faraone, S.V., Kirby, A., et al. (2008). Whole-genome association study of bipolar disorder. *Mol. Psychiatry* 13, 558–569.
- Stanco A, Pla R, Vogt D, Chen Y, Mandal S, Walker J, Hunt RF, Lindtner S, Erdman CA, Pieper AA, Hamilton SP, Xu D, Baraban SC, Rubenstein JL (2014) NPAS1 represses the generation of specific subtypes of cortical interneurons. *Neuron* 84:940-53.
- Takamura N, Nakagawa S, Masuda T, Boku S, Kato A, Song N, An Y, Kitaichi Y, Inoue T, Koyama T, Kusumi I (2014) The effect of dopamine on adult hippocampal neurogenesis. *Prog Neuropsychopharmacol Biol Psychiatry* 50:116-24.

Tao X, Finkbeiner S, Arnold DB, Shaywitz AJ, Greenberg ME (1998) Ca²⁺ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. *Neuron* 20:709-26.

Tao X, West AE, Chen WG, Corfas G, Greenberg ME (2002) A calcium-responsive transcription factor, CaRF, that regulates neuronal activity-dependent expression of BDNF. *Neuron* 33:383-95.

Tao J, Hu K, Chang Q, Wu H, Sherman NE, Martinowich K, Klose RJ, Schanen C, Jaenisch R, Wang W, Sun YE (2009) Phosphorylation of MeCP2 at Serine 80 regulates its chromatin association and neurological function. *Proc Natl Acad Sci USA* 106:4882-7.

Teh DB, Ishizuka H, Yawo H (2014) Regulation of later neurogenic stages of adult-derived neural stem/progenitor cells by L-type Ca channels. *Dev Growth Differ* 56:583-94.

Tesla R, Wolf HP, Xu P, Drawbridge J, Estill SJ, Huntington P, McDaniel L, Knobbe W, Burket A, Tran S, Starwalt R, Morlock L, Naidoo J, Williams NS, Ready JM, McKnight SL, Pieper AA (2012) Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosis. *Proc Natl Acad Sci USA* 109:17016-21.

Walker AK, Rivera PD, Wang Q, Chuang JC, Tran S, Osborne-Lawrence S, Estill SJ, Starwalt R, Huntington P, Morlock L, Naidoo J, Williams NS, Ready JM, Eisch AJ, Pieper AA, Zigman

JM (2015) The P7C3 class of neuroprotective compounds exerts antidepressant efficacy in mice by increasing hippocampal neurogenesis. *Mol Psych* 20:500-8.

Wang G, Han T, Nijhawan D, Theodoropoulos P, Naidoo J, Yadavalli S, Mirzaei H, Pieper AA, Ready JM, McKnight SL (2014) P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage. *Cell* 158:1324-34.

Wessa M, Linke J, Witt SH, Nieratschker V, Esslinger C, Kirsch P, Grimm O, Hennerici MG, Gass A, King AV, Rietschel M (2010) The CACNA1C risk variant for bipolar disorder influences limbic activity. *Mol Psychiatry* 15:1126-7.

West AE, Pruunsild P, Timmusk T. (2014) *Neurotrophic Factors*, Vol. 220: Handbook of Experimental Pharmacology, (Lewin G. R., Carter B. D., eds). Springer Berlin Heidelberg, Berlin, Heidelberg.

White JA, McKinney BC, John MC, Powers PA, Kamp TJ, Murphy GG (2008) Conditional forebrain deletion of the L-type calcium channel *CAv1.2* disrupts remote spatial memories in mice. *Learn Mem* 15:1-5.

Wu Q, Li Y, Xiao B (2013) DISC1-related signaling pathways in adult neurogenesis of the hippocampus. *Gene* 518:223-30.

Yin TC, Britt JK, De Jesus-Cortes H, Lu Y, Genova RM, Khan MZ, Voorhees JR, Shao J, Katazman AC, Huntington PJ, Wassink C, McDaniel L, Newell EA, Dutca LM, Naidoo J, Cui H, Bassuk AG, Harper MM, McKnight SL, Ready JM, Pieper AA (2014) P7C3 neuroprotective chemicals block axonal degeneration and preserve function after traumatic brain injury. *Cell Reports* 8:1731-40.

Yu S, Patchev AV, Wu Y, Lu J, Holsboer F, Zhang JZ, Sousa N, Almeida OF (2010) Depletion of the neural precursor cell pool by glucocorticoids. *Ann Neurol* 67: 21–30.

FIGURE LEGENDS

Figure 1. $Ca_v1.2$ supports adult hippocampal neurogenesis. **A, Left**, Graphical representation of the dorsal, medial, and ventral dentate gyrus (DG) in which BrdU⁺ staining was quantified. **Right**, representative images of BrdU- and hematoxylin-stained dentate gyrus from forebrain- $Ca_v1.2$ cKO and wild type (WT) littermate mice. **B**, Forebrain- $Ca_v1.2$ cKO mice show significantly lower BrdU⁺ cells in the dentate gyrus compared to WT animals (**B**, WT n= 4; KO n=4; ** $p = .004$, independent samples t-test). **C, D**, Forebrain- $Ca_v1.2$ cKO mice also show lower DCX protein (**C**, WT n=3; KO n=3) and mRNA levels (**D**, WT n=6; KO n=6, *** $p < .001$, independent-samples t-test) compared to WT animals. All graphs are represented as mean \pm SEM.

Figure 2. Selective elimination of $Ca_v1.2$ in adult dentate gyrus results in lower neurogenesis. **A, Top**, Representative image of GFP-labeled cells within the dentate gyrus of $Ca_v1.2^{fl/fl}$ mice injected with AAV2/2-Cre-GFP; **Bottom**, AAV2/2-Cre-GFP significantly decreased $Ca_v1.2$ mRNA compared to control AAV2/2-GFP injected mice (**A**, AAV2/2-GFP n=5; AAV2/2-Cre n= 5; *** $p < .001$, independent-samples t-test). **B**, Adult focal hippocampal knockout of $Ca_v1.2$ results in significantly lower BrdU⁺ cells in the dentate gyrus (AAV2/2-GFP n=6; AAV2/2-Cre n= 9; **** $p < .0001$, independent-samples t-test). All graphs are represented as mean \pm SEM.

Figure 3. $Ca_v1.2$ controls survival of young hippocampal neurons, associated with lower BDNF levels in the absence of differences in corticosterone levels or hippocampus volume.

A, C, Graphical representation of BrdU pulse chase experiments to determine proliferation (**A**) vs. survival (**C**). (IHC: Immunohistochemistry) **B, D**, Forebrain-Ca_v1.2 cKO mice display normal proliferation as compared to WT animals, with no difference in BrdU⁺ cells one hour after BrdU administration (**B**, WT n=4; KO=3; $p = .935$, independent-samples t-test). Forebrain-Ca_v1.2 cKO mice do, however, show a deficit in survival of young hippocampal neurons, as indicated by significantly lower BrdU⁺ cells in the dentate gyrus 30 days after BrdU injection (**D**, WT n=7; KO n=5, $**p = .002$, independent-samples t-test). Arrows point to BrdU positive cells. **E**, BDNF protein levels are significantly lower in forebrain-Ca_v1.2 cKO mice compared to WT animals (WT n=6, KO n=10, $*p = .005$, independent-samples t-test). **F**, Corticosterone levels are not different between forebrain-Ca_v1.2 cKO mice and WT animals (Basal, WT n=14; KO n=15, Stressed, WT n=15; KO n=7, main effect of basal vs stressed $****p < .0001$, main effect of genotype $p = .4232$, two-way ANOVA). **G**, Nissl staining showed no differences between forebrain-Ca_v1.2 cKO and WT thickness of the dentate gyrus (DG, $p = .986$, independent-samples t-test), CA1 ($p = .518$, independent-samples t-test) and CA3 ($p = .898$, independent-samples Mann-Whitney U test) layers of the hippocampus (WT n= 5; KO n= 9). All graphs are represented as mean \pm SEM.

Figure 4. Treatment with P7C3-A20 restores hippocampal neurogenesis in forebrain-Ca_v1.2 cKO mice without affecting BDNF levels. **A-C**, Treatment with the neuroprotective compound P7C3-A20 significantly increased the levels of BrdU⁺ cells in the dentate gyrus (**A, B**, Veh vs P7C3-A20 $****p < .0001$; WT-Veh n=3, KO-Veh n=3, WT-A20 n=3, KO-A20 n=3), DCX protein levels using immunohistochemistry (**C**), and mRNA levels (**D**, Veh: WT vs KO; $*p = .029$; WT: Veh vs P7C3-A20, $**p = .005$; KO: Veh vs P7C3-A20 $****p < .0001$; WT-Veh

n=8, KO-Veh n=7, WT-A20 n=9, KO-A20 n=8) of both WT and forebrain-Cav1.2 cKO adult animals compared to vehicle-treated groups. **E**, P7C3-A20 had no effect on BDNF protein levels in either group (WT: Veh vs P7C3-A20, $p = .9996$; KO: Veh vs P7C3-A20, $p > .999$; WT-VEH n=8, KO-VEH n=5, WT-A20 n=8, KO-A20 n=6

Visual Abstract. See abstract

Figure 1




Figure 2




Figure 3






Figure 4




Forebrain Cav1.2 cKO



Adult hippocampus

↓ Neurogenesis due to ↓ survival of newborn precursor cells
↓ BDNF levels



- Normalized neurogenesis due to ↑ survival of newborn precursor cells
- No change in BDNF